ArticleMammalian genome : official journal of the International Mammalian Genome Society2025
Alantolactone curbs the malignant progression of bladder cancer partly via the HSP90AB1/LRP5/β-catenin axis.
Article in Mammalian genome : official journal of the International Mammalian Genome Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Bladder cancer (BCa) represents a global health problem. Traditional Chinese medicine has a long history of treating cancers. This study has been conducted to illustrate the anti-cancer effects of alantolactone (ALT) in BCa and to explore the potential mechanism. The effects of ALT on the malignant behavior of T24 and TCCSUP cells were investigated. Bioinformatic methods were utilized to predict potential targets of ALT. Cells were infected with lentiviral overexpression vectors for heat shock protein HSP 90-beta (HSP90AB1) or treated with the β-catenin signaling inhibitor MSAB to explore their effects on BCa cell behaviors. The effects on tumorigenesis were also analyzed in a xenograft tumor model. ALT markedly reduced the proliferation, migration, and invasion of BCa cells and induced apoptosis. ALT treatment was associated with decreased HSP90AB1 levels in BCa cells and increased low-density lipoprotein receptor-related protein 5 (LRP5) ubiquitination, thereby impairing β-catenin activation. HSP90AB1 overexpression attenuated the anti-cancer effects of ALT, while MSAB repressed the malignant progression of BCa cells promoted by HSP90AB1 overexpression. Forced overexpression of HSP90AB1 enhanced BCa development in vivo, which was mitigated by MSAB. In conclusion, our findings suggest that ALT exerts anti-cancer activity in BCa, potentially through modulation of HSP90AB1 and β-catenin signaling pathways.
Indexed as
Identifiers
41436627What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.